First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) Trading 1.1% Higher - Here's What Happened

Key Points

• LON:FBT rose 1.1% on Thursday to GBX 1,881.80, but trading volume was light at about 198 shares, down ~67% from its average of 605 shares.
• The fund has a market capitalization of £771.94 million and an unusually negative PE of -1,710.73; its 50‑day and 200‑day simple moving averages are GBX 1,919.69 and GBX 1,812.03, respectively.
• The article's "About" section appears misattributed, describing Forbidden Technologies plc (Blackbird) rather than the ETF.

Shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - ) rose 1.1% during trading on Thursday . The stock traded as high as GBX 1,881.80 and last traded at GBX 1,881.80. Approximately 198 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 605 shares. The stock had previously closed at GBX 1,861.40.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Performance

The company has a market capitalization of £771.94 million and a PE ratio of -1,710.73. The company's 50-day simple moving average is GBX 1,919.69 and its 200-day simple moving average is GBX 1,812.03.

About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation

Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.